Increased release and activity of matrix metalloproteinase‐9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome
Authors:
- D’a PiceDPD’a Pice
- P BorgianiPBP Borgiani
- M ColettaMCM Coletta
- G NovelliG Novelli
- 16 September 2008
- journal article
- Published by Wiley in Clinical Genetics
- Vol. 74 (4) , 374-383
Abstract
Mandibuloacral dysplasia type A (MADA; OMIM 248370), a rare disorder caused by mutation in theLMNAgene, is characterized by post‐natal growth retardation, craniofacial and skeletal anomalies (mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of cranial sutures, low bone mass and joint contractures), cutaneous changes and partial lipodystrophy. Little is known about the molecular mechanisms by whichLMNAmutations produce bone alterations. An altered bone extracellular matrix (ECM) remodelling could play a pivotal role in this disorder and influence part of the typical bone phenotype observed in patients. Therefore, we have focused our investigation on matrix metalloproteinases (MMPs), which are degradative enzymes involved in ECM degradation and ECM remodelling, thus likely contributing to the altered bone mineral density and bone metabolism values seen in five MADA patients. We evaluated the serum levels of several MMPs involved in bone development, remodelling and homeostasis, such as MMP‐9, ‐2, ‐3, ‐8 and ‐13, and found that only the 82 kDa active enzyme forms of MMP‐9 are significantly higher in MADA sera compared with healthy controls (n = 16). The serum level of MMP‐3 was instead lower in all patients. No significant differences were observed between controls and MADA patients for the serum levels of MMP‐2, ‐8 and ‐13 and of tissue inhibitor of metalloproteinase 2, a natural inhibitor of MMP‐9. Similarly, normal serum levels of tumour necrosis factor alpha (TNF‐α), interleukin (IL)‐6 and IL‐1β were detected. These data suggest a possible involvement of MMP‐9 in MADA disease, underlying the potential use in diagnosis and therapy.Keywords
This publication has 58 references indexed in Scilit:
- Mandibuloacral dysplasia and a novel LMNA mutation in a woman with severe progressive skeletal changesAmerican Journal of Medical Genetics Part A, 2007
- Matrix metalloproteinases: role in skeletal development and growth plate disordersFrontiers in Bioscience-Landmark, 2006
- Role and Function of Matrix Metalloproteinases in the Differentiation and Biological Characterization of Mesenchymal Stem CellsStem Cells, 2005
- Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targetsArthritis & Rheumatism, 2001
- Elevation of Serum Levels of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-1 and Type IV Collagen, and Plasma Levels of Metalloproteinase-9 in Polycystic Kidney DiseaseAmerican Journal of Nephrology, 2000
- Role of Matrix Metalloproteinases in Human Periodontal Diseases*Journal of Periodontology, 1993
- Role of Matrix Metalloproteinases in Human Periodontal DiseasesJournal of Periodontology, 1993
- A 25 kDa α2‐microglobulin‐related protein is a component of the 125 kDa form of human gelatinaseFEBS Letters, 1992
- The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritisArthritis & Rheumatism, 1990
- Human gelatinase/type IV procollagenase is a regular plasma componentFEBS Letters, 1989